Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Mar;25(3):387–396. doi: 10.1111/j.1365-2125.1988.tb03318.x

Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).

R A Prentis 1, Y Lis 1, S R Walker 1
PMCID: PMC1386364  PMID: 3358900

Abstract

1 A total of three hundred and nineteen new chemical entities (NCEs) were investigated in man for the first time between 1964 and 1985 by seven UK-owned pharmaceutical companies. The majority (96.2%), were self-originated by the UK company or one of its overseas subsidiaries. 2 There was an increase in the number of NCEs investigated each year in man, doubling from an average of 12 per year up to 1980, to over 20 per year between 1981 and 1985. The majority of first drug evaluations in human volunteers were carried out in the UK (92.2%), in contrast to evaluation of new medicines in patients, where 42.9% were first tested outside the UK. 3 The majority of NCEs evaluated in man (78%), were in four therapeutic classes: anti-infectives (32%), anti-allergics (22%), drugs acting on the central nervous system (13%) and cardiovascular system agents (11%). 4 By the end of 1985, 49 (15.4%) of these NCEs had been marketed in the UK and 198 (62.0%) discontinued from further development. The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%). 5 Average development times increased from less than 2 years between 1964 and 1965, to around 8 years in the 1980s with a consequent reduction in the effective patent life.

Full text

PDF
387

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Griffin J. P., Diggle G. E. A survey of products licensed in the United Kingdom from 1971-1981. Br J Clin Pharmacol. 1981 Oct;12(4):453–463. doi: 10.1111/j.1365-2125.1981.tb01251.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Griffin J. P., Stewart A. G. Six months experience of new procedures affecting the conduct of clinical trials in the United Kingdom. Br J Clin Pharmacol. 1982 Feb;13(2):253–255. doi: 10.1111/j.1365-2125.1982.tb01374.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Mattison N., Thomas E., Trimble A. G., Wardell W. M. The development of self-originated new drugs by Swiss pharmaceutical firms, 1960-1980. Regul Toxicol Pharmacol. 1984 Jun;4(2):157–173. doi: 10.1016/0273-2300(84)90038-2. [DOI] [PubMed] [Google Scholar]
  4. Prentis R. A., Walker S. R. Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980). Br J Clin Pharmacol. 1986 Apr;21(4):437–443. doi: 10.1111/j.1365-2125.1986.tb05219.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Speirs C. J., Griffin J. P. A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom. Br J Clin Pharmacol. 1983 Jun;15(6):649–655. doi: 10.1111/j.1365-2125.1983.tb01545.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Steward F., Wibberley G. Drug innovation--what's slowing it down? Nature. 1980 Mar 13;284(5752):118–120. doi: 10.1038/284118a0. [DOI] [PubMed] [Google Scholar]
  7. Wardell W. M., DiRaddo J. The measurement of pharmaceutical innovation. J Clin Pharmacol. 1980 Jan;20(1):1–9. doi: 10.1002/j.1552-4604.1980.tb01660.x. [DOI] [PubMed] [Google Scholar]
  8. Wardell W. M., Hassar M., Anavekar S. N., Lasagna L. The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther. 1978 Aug;24(2):133–145. doi: 10.1002/cpt1978242133. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES